Central nervous system leukemia.
The treatment of central nervous system (CNS) leukemia still poses a significant challenge to the clinical oncologist despite significant advances in therapeutic strategies that are directly targeted at the CNS. This article reviews the evolving definition of CNS leukemia, the current status of therapy for the prevention and treatment of overt CNS leukemia, pharmacological considerations in the treatment of CNS leukemia, and the longterm sequelae of CNS-directed therapy, focusing on articles that have been published in the past 2 years. New agents and treatment strategies for the treatment and prevention of CNS leukemia are also discussed.
Blaney
S M
SM
Department of Pediatrics, Baylor College of Medicine, Houston, TX 77024, USA.
Poplack
D G
DG
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000175:diagnosis / Q000628:therapy; D002493:Central Nervous System Diseases / Q000628:therapy*; D003131:Combined Modality Therapy; D015316:Genetic Therapy; D006801:Humans; D007278:Injections, Spinal; D007938:Leukemia / Q000175:diagnosis / Q000628:therapy*; D008577:Meningeal Neoplasms / Q000188:drug therapy
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents